The 72nd Annual Conference on Mass Spectrometry, Japan
Date:
Mon, Jun 10, - Wed, Jun 12, 2024
Venue:
Tsukuba International Congress Center (Takezono, Tsukuba City, Ibaraki Prefecture 305-0032, Japan)
  •  
  •  
  •  
  •  

Abstract

Poster Presentations

Day 2, June 11(Tue.)  Room P1 (Multipurpose Hall)・Room P2 (Conference Room 101+102)

2P-30
PDF

Optimization Study of Drug to Antibody Ratio (DAR) Analysis by Native SEC-MS

(Astellas Pharma.)
oRyuto Nakae, Taishi Kusama, Masahiro Mimura, Yutaka Hirakura

Antibody-drug conjugates (ADCs) are one of the important modalities in cancer treatments. ADCs consist of a monoclonal antibody (mAb) attached to drugs via linkers. The potency of ADCs primarily depends on the drug to antibody ratio (DAR), which refers to the average number of drugs bound to the mAb. DAR is therefore considered as one of the critical quality attributes (CQA) of ADCs. To perform the analysis in native conditions, size-exclusion chromatography with mass spectrometry (SEC-MS) is one of the promising methods. There are some difficulties in accurately determining DAR using SEC-MS. Here, we investigated various MS measurement parameters to accurately determine DAR by performing SEC-MS measurements while maintaining the ADC structure. We identified vaporizer temperature as a critical parameter to maintain the structure during SEC-MS measurements. Other MS measurement parameters affected the peak intensity but not the structure of the ADC. Next, various ADCs were prepared by conjugating several types of mAbs and DLs in each combination. The prepared ADCs were measured by SEC-MS and the effect of glycan digestion and differences in analysis methods were evaluated from the obtained DAR values. Under optimized conditions, which allow us to obtain simpler mass spectra, DAR values can be measured more robustly.